Geode Capital Management LLC Has $229.50 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Geode Capital Management LLC grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,802,888 shares of the company's stock after buying an additional 102,106 shares during the quarter. Geode Capital Management LLC owned approximately 2.25% of Vaxcyte worth $229,495,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Diversified Trust Co acquired a new position in Vaxcyte in the 4th quarter valued at approximately $1,433,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Vaxcyte by 23.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after acquiring an additional 4,962 shares during the last quarter. TimesSquare Capital Management LLC raised its holdings in shares of Vaxcyte by 53.7% during the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after acquiring an additional 144,516 shares in the last quarter. Principal Financial Group Inc. boosted its position in Vaxcyte by 186.2% during the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock valued at $6,022,000 after purchasing an additional 34,287 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Vaxcyte by 70.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after purchasing an additional 246,049 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Remove Ads

Vaxcyte Price Performance

Shares of PCVX traded down $2.63 during midday trading on Thursday, hitting $28.17. The stock had a trading volume of 621,331 shares, compared to its average volume of 1,782,906. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of -6.12 and a beta of 1.26. The company has a 50 day simple moving average of $68.64 and a two-hundred day simple moving average of $86.91. Vaxcyte, Inc. has a twelve month low of $27.80 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. Analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on PCVX shares. The Goldman Sachs Group decreased their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Bank of America dropped their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $136.50.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at $9,472,066.41. This trade represents a 6.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares of the company's stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock worth $3,170,738 in the last ninety days. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.